Semaglutide injection pens and packaging on a table in a modern pharmaceutical facility.
Alkem Laboratories has launched a semaglutide injection in India, aiming to capitalize on the expanding market for diabetes and weight loss treatments. The drug, available under the brand names Semasize and Obesema, is administered once weekly.
Alkem’s offering includes a pre-filled pen, providing a month’s dosage at a cost of Rs 1,800, which translates to Rs 450 per week. This positions Alkem as a competitive player in the rapidly growing weight management sector.
The introduction of Semaglutide by Alkem Labs provides a more accessible option for patients seeking treatment for diabetes and weight management in India, potentially impacting the market dynamics and patient access to these therapies.
About the Author
